Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial by Xiaomin He, Emiliano Calvo, David F McDermott, Valentina Boni, Olivier Dumas, Arvind Chaudhry, Sang Joon Shin, Seth D Rosen, Philip R Debruyne, Ulka N Vaishampayan

Get full text

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

Get full text

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1) by Lucy Gilbert, Jameel Muzaffar, Vamsidhar Velcheti, Anna Spreafico, Emiliano Calvo, David F McDermott, Marc S Ernstoff, Valentina Boni, Karl D Lewis, Ira Winer, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Christoper J Hoimes, Seth D Rosen, Debora S Bruno, James F Strauss, Rita Dalal, Ulka N Vaishampayan, Quincy S Chu

Get full text